This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Roberts, W. G. Articles by Vajdos, F. Search for Related Content PubMed PubMed Citation Articles by Roberts, W. G. Articles by Vajdos, F.

Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271

Pfizer Oncology, Groton, Connecticut

Requests for reprints: Walter Gregory Roberts, Oncovia Therapeutics, 100 Plaza Court #479, Groton, CT 06340. E-mail: robertswg{at}oncoviarx.com.

Key Words: focal adhesion kinase • PF-562,271

Cancer cells are characterized by the ability to grow in an anchorage-independent manner. The activity of the nonreceptor tyrosine kinase, focal adhesion kinase (FAK), is thought to contribute to this phenotype. FAK localizes in focal adhesion plaques and has a role as a scaffolding and signaling protein for other adhesion molecules. Recent studies show a strong correlation between increased FAK expression and phosphorylation status and the invasive phenotype of aggressive human tumors. PF-562,271 is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 catalytic activity with a IC₅₀ of 1.5 and 14 nmol/L, respectively. Additionally, PF-562,271 displayed robust inhibition in an inducible cell-based assay measuring phospho-FAK with an IC₅₀ of 5 nmol/L. PF-562,271 was evaluated against multiple kinases and displays >100x selectivity against a long list of nontarget kinases. PF-562,271 inhibits FAK phosphorylation in vivo in a dose-dependent fashion (calculated EC₅₀ of 93 ng/mL, total) after p.o. administration to tumor-bearing mice. In vivo inhibition of FAK phosphorylation (>50%) was sustained for >4 hours with a single p.o. dose of 33 mg/kg. Antitumor efficacy and regressions were observed in multiple human s.c. xenograft models. No weight loss, morbidity, or mortality were observed in any in vivo experiment. Tumor growth inhibition was dose and drug exposure dependent. Taken together, these data show that kinase inhibition with an ATP-competitive small molecule inhibitor of FAK decreases the phospho-status in vivo, resulting in robust antitumor activity. [Cancer Res 2008;68(6):1935–44]

This article has been cited by other articles:

				J. K. Slack-Davis, E. D. Hershey, D. Theodorescu, H. F. Frierson, and J. T. Parsons Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model Mol. Cancer Ther., August 1, 2009; 8(8): 2470 - 2477. [Abstract] [Full Text] [PDF]

				H. K. Gan and L. L. Siu Focal Adhesion Kinase as a Therapeutic Target in Cancer ASCO Educational Book, January 1, 2009; 2009(1): 130 - 136. [Abstract] [Full Text] [PDF]

				E. Behmoaram, K. Bijian, S. Jie, Y. Xu, A. Darnel, T. A. Bismar, and M. A. Alaoui-Jamali Focal Adhesion Kinase-Related Proline-Rich Tyrosine Kinase 2 and Focal Adhesion Kinase Are Co-Overexpressed in Early-Stage and Invasive ErbB-2-Positive Breast Cancer and Cooperate for Breast Cancer Cell Tumorigenesis and Invasiveness Am. J. Pathol., November 1, 2008; 173(5): 1540 - 1550. [Abstract] [Full Text] [PDF]

				S. M. Weis, S.-T. Lim, K. M. Lutu-Fuga, L. A. Barnes, X. L. Chen, J. R. Gothert, T.-L. Shen, J.-L. Guan, D. D. Schlaepfer, and D. A. Cheresh Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK J. Cell Biol., April 3, 2008; 181(1): 43 - 50. [Abstract] [Full Text] [PDF]